Skip to main content
COGT
NASDAQ Life Sciences

Director-Affiliated Fund Files Intent to Sell $127.4M in Cogent Biosciences Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$39.53
Mkt Cap
$6.011B
52W Low
$3.72
52W High
$43.73
52W Position info
963% above low
Off High info
9.6% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

COGT has more than doubled off its 52-week low of $3.72.

Summary

A fund associated with a director of Cogent Biosciences has filed a Form 144 to sell 3.5 million shares, valued at $127.4 million, indicating a significant insider-affiliated disposition.


Key Events · Ownership and Investor Activity · COGT

  • Director-Affiliated Fund Files Intent to Sell

    Fairmount Healthcare Fund II L.P., an entity associated with director Peter Harwin, filed a Form 144 to sell 3,500,000 shares of common stock.

  • Significant Proposed Sale Value

    The proposed sale has an approximate market value of $127.4 million, representing a substantial portion of the company's market capitalization.


Analysis · COGT · Life Sciences

Fairmount Healthcare Fund II L.P., an entity associated with Peter Harwin, a director of Cogent Biosciences, has filed a Form 144 indicating its intent to sell 3,500,000 shares. This proposed sale, valued at approximately $127.4 million, represents a significant portion of the company's market capitalization. Such a large insider-affiliated disposition could signal a lack of confidence or a strategic portfolio adjustment by a key investor, potentially creating downward pressure on the stock.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COGT - Latest Insights

COGT
Nov 05, 2026, 4:28 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $26.79 info
Change: -$2.42 (-8%) info
Market Cap: $4.669B info
COGT
Nov 05, 2026, 4:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $29.21
Real-time Price: $26.79 info
Change: -$2.42 (-8%) info
Market Cap: $4.669B info
COGT
Sep 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.50
Real-time Price: $26.79 info
Change: -$6.71 (-20%) info
Market Cap: $4.669B info
COGT
Aug 10, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.53
Real-time Price: $26.79 info
Change: -$14.74 (-35%) info
Market Cap: $4.669B info
COGT
Aug 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $40.55
Real-time Price: $26.79 info
Change: -$13.76 (-34%) info
Market Cap: $4.669B info